Evidence map›Paper›PMID 31938426›Full record

ArticleInternational journal of clinical and experimental pathology2018

MMP2 is associated with glioma malignancy and patient outcome.

Rūta Sincevičiūtė, Paulina Vaitkienė, Rūta Urbanavičiūtė, Giedrius Steponaitis, Arimantas Tamašauskas, Daina Skiriutė

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Role of scaffold proteins in the heterogeneity of glioblastoma.Cell communication and signaling : CCS · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. ADAMDEC1 accelerates GBM progressionFrontiers in oncology · 2022
    Article
  15. Article
  16. Targeting RGS4 Ablates Glioblastoma Proliferation.International journal of molecular sciences · 2020
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rūta SincevičiūtėLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences Kaunas, Lithuania.
Paulina VaitkienėLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences Kaunas, Lithuania.
Rūta UrbanavičiūtėLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences Kaunas, Lithuania.
Giedrius SteponaitisLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences Kaunas, Lithuania.
Arimantas TamašauskasLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences Kaunas, Lithuania.
Daina SkiriutėLaboratory of Molecular Neurooncology, Neuroscience Institute, Lithuanian University of Health Sciences Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are fast growing and usually manifest in an aggressive infiltrative model.

Indexed as

DNA methylationELISAgene expressiongliomaMatrix metallopeptidase 2protein array

Identifiers

PMID31938426
PMCPMC6958083
OpenAlexW3007651612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.